Pre-clinical Services

A critical first step on the drug development journey is the manufacture of preclinical material for further evaluation, including IND enabling toxicology studies. The manufacturing process and analytical methodology should be defined and should provide a reasonable scientific basis for characterizing the product. The supply chain of key raw materials is investigated to ensure TSE compliant manufacture. Avecia offers an organization dedicated to rapidly responding to your needs, solid, cost-effective manufacturing and analytical capability to facilitate IND filing and unrivalled experience in the industry.

A strategic alliance between Avecia OligoMedicines and TriLink Biotechnologies offers our customers a rapid, cost-competitive source for small quantities (typically less than a gram) of non-cGMP oligonucleotides. By exclusively licensing Avecia’s technology to a technically proficient partner, our customers can benefit from TriLink’s flexibility and rapid turnaround times while maintaining a straightforward process transfer to Avecia as clinical material needs are further defined.